heat shock protein family B (small) member 6Genealiases: HEL55 · Hsp20 · PPP1R91
Q-omics provides the consensus-scored HSPB6 profile across patient tissues and cancer cell-line models. HSPB6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HSPB6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, HSPB6 protein abundance shows 28,931 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KIRC, and LUAD as cancer lineages where HSPB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPB6 survival associations across molecular data types. HSPB6 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPB6 RNA expression–survival associations across cancer types. High HSPB6 expression shows unfavorable associations in BLCA, KIRP, LGG, MESO and LUAD, but favorable associations in COAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for HSPB6 RNA expression.
This table summarizes HSPB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSPB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPB6 shows lower tumor expression in KIRC, BLCA, KICH, THCA, LUAD and COAD. The KIRC box plot shows higher HSPB6 RNA expression in normal versus tumor tissue (log2 FC = −1.938, t-test p < 0.001).
This table shows molecular features associated with HSPB6 in patient tissues and cancer cell lines. In patient samples, HSPB6 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
